Article

Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study

2021-04-20

Abstract excerpt

<h4>Background</h4> Several anti-cytokine therapies were tested in the randomized trials in hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection (COVID-19). Both janus kinase (JAK) inhibitor, baricitinib, and dexamethasone demonstrated the reduction of mortality. In this matched control study we compared dexamethasone to another JAK inhibitor, ruxolitinib. <h4>Methods</h4> The study...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7990af79-9c83-5106-9ea2-1465e8609684
DOI: 10.1101/2021.04.20.21255662

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled studyDOI 10.1101/2021.04.20.21255662Read

Ruxolitinib Versus Dexamethasone in Hospitalized Adults With COVID-19: Multicenter Matched Cohort StudySemantic proximity Read

Comparative Effectiveness of Dexamethasone in Treatment of Hospitalized COVID-19 Patients during the First Year of the Pandemic: The N3C Data RepositorySemantic proximity Read

The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trialsSemantic proximity Read

Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirementSemantic proximity Read

Outcomes of Patients with COVID-19 in the Setting of Chronic Opioid Use DisorderSemantic proximity Read

On whether therapeutic plasma exchange is an effective cure against severe/critical COVID-19 pneumoniaSemantic proximity Read

A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1Semantic proximity Read

On Whether Therapeutic Plasma Exchange is Effective Against Severe/Critical COVID-19 PneumoniaSemantic proximity Read

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.Semantic proximity Read

Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and PharmacodynamicsSemantic proximity Read

The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expectSemantic proximity Read